Tuberculosis treatment: Dangerous regimens?

International Journal of Tuberculosis and Lung Disease

Volumn 5, Issue 1, 2001, Pages 1-3

  Rieder, H L ^a   Arnadottir, T ^a   Trebucq A ^a   Enarson, D A ^a  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ANTIMICROBIAL ACTIVITY; CLINICAL TRIAL; DRUG CHOICE; EPIDEMIC; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MONOTHERAPY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; SEROLOGY; SPUTUM EXAMINATION; TREATMENT FAILURE; TREATMENT PLANNING; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHAMBUTOL; HUMANS; ISONIAZID; PYRAZINAMIDE; RIFAMPIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; WORLD HEALTH ORGANIZATION;

EID: 0035035646     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Treatment of tuberculosis: Guidelines for national programmes
2. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid
3. Rifapentine
4. Drug malabsorption and resistant tuberculosis in HIV-infected patients
5. Risk factors for rifampin-monoresistant tuberculosis. A case-control study
6. Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis
7. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report
8. A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis
9. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. First report
10. Progress in global tuberculosis control 1995-1996, with an emphasis on 22 high-incidence countries
11. Global surveillance for antituberculosis-drug resistance, 1994-1997
12. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. First report
13. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report
14. Prevalence of primary and acquired resistance of Mycobacterium tuberculosis to antituberculosis drugs in Benin after 12 years of short-course chemotherapy
15. Primary resistance to antituberculosis drugs: A national survey conducted in Côte d'Ivoire in 1995-1996
16. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana
17. The prognosis of open pulmonary tuberculosis
18. Survival rates in pulmonary tuberculosis
19. Epidemiological basis of tuberculosis eradication. 9. Changes in mortality of Danish tuberculosis patients since 1925
20. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis
21. Evaluation of young children in household contact with adult multidrug-resistant pulmonary tuberculosis cases
22. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment